Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Ketamine Hydrochloride
Therapeutic Area : Neurology
Study Phase : Phase III
Recipient : PharmaTher
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Under the collaboration, PharmaTher will be responsible for regulatory, manufacturing and supply of Ketarx (ketamine hydrochloride), an FDA-approved NMDA receptor-modulating drug, and Vitruvias will be responsible for the marketing, sales, and distributi...
Brand Name : Ketarx
Molecule Type : Small molecule
Upfront Cash : Undisclosed
June 20, 2023
Lead Product(s) : Ketamine Hydrochloride
Therapeutic Area : Neurology
Highest Development Status : Phase III
Recipient : PharmaTher
Deal Size : Undisclosed
Deal Type : Collaboration
LOOKING FOR A SUPPLIER?